Formed in the mid-1990s, the Forum consists of many of the top 20 biopharmaceutical companies. Its focus is to employ careful analysis of R&D data to answer critical business questions, offering accurate, blinded cross-company assessment. As its sole consulting firm facilitator, KMR has worked with the Forum over the years to establish rigorous processes and instructions for the definition and collection of data.
The scope of the Forum extends across the full R&D spectrum, from a detailed examination of Discovery to an annual review of the full R&D pipeline performance, including success rates by therapy area, cycle time, recent activity, licensing, and productivity. Specialist studies have included Pharmaceutical Development, Project Cost, Licensing, Early Clinical Development, Project Management, Portfolio Management, Capacity Management, Preclinical Development.